ALDX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
5.9M
+64.9%
3.5M
-46.8%
6.7M
-16.7%
8.0M
-21.3%
10.2M
R&D
3.5M
+44.6%
2.4M
-44.0%
4.3M
-20.8%
5.4M
-36.1%
8.5M
SG&A
2.4M
+108.0%
1.1M
-51.9%
2.4M
-8.0%
2.6M
+54.5%
1.7M
Operating Income
-5850507
-64.9%
-3546918
+46.8%
-6667883
+16.7%
-8001132
+21.3%
-10168732
EBITDA
-5779801
-66.1%
-3480319
+47.3%
-6602767
+16.8%
-7937449
+21.5%
-10106450
Net Income
-5450273
-57.9%
-3452619
+46.6%
-6461507
+16.0%
-7688341
+21.3%
-9767312
EPS (Basic)
$-0.09
-50.0%
$-0.06
+45.5%
$-0.11
+15.4%
$-0.13
+18.8%
$-0.16
EPS (Diluted)
$-0.09
-50.0%
$-0.06
+45.5%
$-0.11
+15.4%
$-0.13
+18.8%
$-0.16
Shares (Diluted)
60.3M
+0.0%
60.3M
+0.3%
60.2M
+0.1%
60.1M
+0.1%
60.0M
Aldeyra Therapeutics (ALDX) โ€” Financials